Choroideremia Research Foundation Acquires Spark Therapeutics Gene Therapy Assets to Advance Rare Disease Treatment
核心洞察
The Choroideremia Research Foundation (搜索) acquired all assets related to Spark Therapeutics (搜索)' SPK-7001 gene therapy program after the company discontinued development in 2025.
The acquired assets include intellectual property rights, biological materials, orphan drug designations, and Phase I/II clinical trial data from 15 participants.
CRF is analyzing five-year follow-up data with University of Virginia researchers to identify clinical endpoints that can establish vision stabilization following treatment.
The Choroideremia Research Foundation (搜索) (CRF) has acquired all assets related to Spark Therapeutics (搜索)' discontinued SPK-7001 gene therapy program for choroideremia (搜索), marking a first-of-its-kind asset transfer in rare disease research. The acquisition, completed in 2025, includes comprehensive intellectual property rights, biological materials, orphan drug designations, Phase I/II clinical trial data, and Natural History Study data.
Gene Therapy Trial Results Drive Acquisition Decision
Spark Therapeutics (搜索)' clinical trial evaluated the safety and preliminary efficacy of subretinal CHM (搜索) gene therapy (AAV2-hCHM-101 (搜索)) in 15 participants affected by choroideremia (搜索), an inherited retinal disease. The trial design used one treated eye with the other eye serving as a control. While the safety goal was met, some participants have self-reported stabilization in the treated eye, prompting CRF to conduct a comprehensive analysis of the five-year follow-up data.
The acquired clinical data represents valuable insights into gene therapy approaches for this rare condition, which affects approximately 1 in 50,000 people globally. Due to its X-linked inheritance pattern, males are most severely affected, with females usually experiencing much milder visual impairment.
Collaborative Data Analysis Initiative
CRF is partnering with University of Virginia faculty members Drs. Tom and Shannon Barker, along with CRF Chief Science Officer Dr. Mike McConnell, to facilitate a University of Virginia Biomedical Engineering Student Capstone Project titled "Clinical Trial Data Analysis: Finding endpoints that matter to choroideremia (搜索) patients." The student team is evaluating data from ophthalmic measurements completed during Spark's clinical trial.
The analysis addresses a critical challenge in choroideremia (搜索) research: distinguishing therapeutic effects from normal variability between treated and untreated eyes over typical clinical trial timeframes. Given the slow and uneven progression of CHM (搜索), establishing meaningful clinical endpoints has proven difficult for researchers and regulatory authorities.
Natural History Data Integration
The evaluation of Spark's clinical trial data is being conducted alongside an assessment of natural history data from clinical observations of over 125 CHM (搜索) patients. This comprehensive approach aims to identify ophthalmic endpoints that can establish vision stabilization or improvement following therapeutic treatment.
CRF plans to publish these findings to inform regulatory action and approval for any potential future research or clinical trials related to Spark's gene therapy or other choroideremia (搜索) treatments. The foundation's analysis could provide crucial guidance for the development of meaningful clinical endpoints in rare retinal disease research.
Addressing Unmet Medical Need
Choroideremia (搜索) symptoms begin in early childhood, with night blindness and restriction of visual field being the earliest noticeable effects, eventually progressing to complete blindness. An estimated 6,000 people in the United States and 10,000 in the European Union are impacted by choroideremia. Currently, there are no approved treatments for this condition.
The Choroideremia Research Foundation (搜索), founded in 2000, has provided approximately $6 million in research awards and serves as the largest financial supporter of CHM (搜索) research worldwide. Research funded by CRF has led to the development of a CHM animal model, pre-clinical production of gene therapy vectors currently in clinical trials, and the CRF Biobank, which stores tissue and stem cell samples donated by CHM patients.
The foundation acknowledged support from collaborators at Spark, Roche, University of Pennsylvania, and the Children's Hospital of Philadelphia for their assistance in this asset transfer and data review process.